FUT1 and graft versus host disease: Minimizing the risk of serious GVHD is a critical first step to enabling the effective delivery and function of hematopoietic-restricted, minor H antigen-specific T cells, since the management of GVHD requires pharmacologic immunosuppression that is not conducive to T cell expansion and function.